TribLIVE

| USWorld


 
Larger text Larger text Smaller text Smaller text | Order Photo Reprints

FDA grants approval for multiple sclerosis medication

Email Newsletters

Click here to sign up for one of our email newsletters.

Daily Photo Galleries

By The Los Angeles Times
Thursday, March 28, 2013, 6:33 p.m.
 

WASHINGTON — An oral medication for multiple sclerosis has won the Food and Drug Administration's marketing approval and is to become available almost immediately to patients suffering from the debilitating auto-immune disease.

Tecfidera is the commercial name for dimethyl fumarate, a capsule that won the FDA's blessing this week as a treatment for relapsing MS, a degenerative brain disorder that can impair mobility, sensation and thinking.

In clinical trial evidence submitted to the FDA by Biogen Idec of Weston, Mass., the medication's maker, Tecfidera reduced the proportion of patients who relapsed when compared with a sham medication. In one of those trials, subjects taking Tecfidera showed less progression of the disease compared with those on a placebo. And both trials found that those taking Tecfidera twice daily developed fewer MS-related lesions in the brain.

The medication was formerly known as BG-12.

Those findings held whether patients had newly diagnosed multiple sclerosis or had their multiple sclerosis progress over some years, said Dr. Robert M. Fox, medical director of the Mellen Center for Multiple Sclerosis at the Cleveland Clinic, in a statement issued by Biogen Idec. Fox serves as a paid adviser to the firm and was lead investigator in one of the Tecfidera's earliest trials.

Common side effects of Tecfidera are flushing and gastrointestinal events, including nausea, diarrhea and vomiting. And though no increased rate of infections were noted in those taking Tecfidera in clinical trials, the medication may lower white blood counts and increase infection risk, the FDA said.

Subscribe today! Click here for our subscription offers.

 

 


Show commenting policy

Most-Read Nation

  1. Accused Texas gunman was former target of FBI terror probe
  2. Obama chooses Marine commandant as new Joint Chiefs chairman
  3. Ex-CIA deputy: Benghazi distorted
  4. Trucking interests trump safety in $55.3B transportation spending bill
  5. Clinton interview vexes wife’s backers
  6. Police: Georgia sheriff shot woman, would not give statement
  7. Researchers find new, elusive bird species
  8. FBI tracked Texas cartoon contest shootings suspect
  9. Poisoned teens still in critical condition
  10. Texas Legislature acts to stop cities from limiting drilling
  11. Pentagon dismisses Texas concern over special operations exercise